These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 25768994)

  • 21. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study.
    Li W; Chang Y; Liu X; Chen Z; Sun J; Geng Z; Zhang M; Zhang L
    Ann Hematol; 2024 Jun; 103(6):2003-2012. PubMed ID: 38308020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG
    Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine.
    Yalin SF; Trabulus S; Yalin AS; Yalin GY; Ongoren S; Altiparmak MR
    Int J Clin Pharm; 2013 Jun; 35(3):306-8. PubMed ID: 23338712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haematological cancer: Bortezomib in MCL--new standard of care or just another option?
    Dreyling M
    Nat Rev Clin Oncol; 2015 Jul; 12(7):376-8. PubMed ID: 26011491
    [No Abstract]   [Full Text] [Related]  

  • 25. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
    Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
    Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
    Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
    Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
    [No Abstract]   [Full Text] [Related]  

  • 29. Subcutaneous rituximab and chemotherapy achieves similar overall response rates to intravenous rituximab in first-line follicular lymphoma: efficacy and safety results of the phase III SABRINA study.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):6-7. PubMed ID: 25768992
    [No Abstract]   [Full Text] [Related]  

  • 30. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.
    Kumar R; Galardy PJ; Dogan A; Rodriguez V; Khan SP
    Pediatr Blood Cancer; 2011 Aug; 57(2):317-20. PubMed ID: 21462303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
    Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A
    Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
    Castellino A; Wang Y; Larson MC; Maurer MJ; Link BK; Farooq U; Feldman AL; Syrbu SI; Habermann TM; Paludo J; Inwards DJ; Witzig TE; Ansell SM; Allmer C; Slager SL; Cohen JB; Martin P; Cerhan JR; Nowakowski GS
    Blood Adv; 2022 Feb; 6(4):1350-1360. PubMed ID: 34662895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
    Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
    Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
    Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
    Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.
    Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ
    Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.